77 related articles for article (PubMed ID: 38441839)
1. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine.
Wildemberg LE; Fialho C; Gadelha MR
Best Pract Res Clin Endocrinol Metab; 2024 May; ():101906. PubMed ID: 38845246
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor ligands in the treatment of acromegaly.
Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
4. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
5. Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands.
Herkenhoff CGB; Trarbach EB; Batista RL; Soares IC; Frassetto FP; do Nascimento FBP; Grande IPP; Silva PPB; Duarte FHG; Bronstein MD; Jallad RS
J Clin Endocrinol Metab; 2023 Mar; 108(4):876-887. PubMed ID: 36273993
[TBL] [Abstract][Full Text] [Related]
6. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling for acromegaly treatment: a validation study.
Puig-Domingo M; Gil J; Sampedro-Nuñez M; Jordà M; Webb SM; Serra G; Pons L; Salinas I; Blanco A; Marques-Pamies M; Valassi E; Picó A; García-Martínez A; Carrato C; Buj R; Del Pozo C; Obiols G; Villabona C; Cámara R; Fajardo-Montañana C; Alvarez CV; Bernabéu I; Marazuela M
Endocr Relat Cancer; 2020 Jun; 27(6):375-389. PubMed ID: 32302973
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Non-alcoholic Fatty Liver Disease and RCA Pericoronary Adipose Tissue CT Attenuation in Patients with Acute Chest Pain.
Yang W; Wen D; Li S; Zhao H; Xu J; Liu J; Chang Y; Xu J; Zheng M
Acad Radiol; 2024 May; 31(5):1773-1783. PubMed ID: 38160090
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly.
Marques-Pamies M; Gil J; Jordà M; Puig-Domingo M
Arch Med Res; 2023 Dec; 54(8):102924. PubMed ID: 38042683
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.
Chen M; Bie L; Ying J
Biomed Pharmacother; 2023 Nov; 167():115514. PubMed ID: 37716115
[TBL] [Abstract][Full Text] [Related]
13. Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.
Chiloiro S; Frara S; Gagliardi I; Bianchi A; Giampietro A; Medici M; Allora A; di Filippo L; Ambrosio MR; Pontecorvi A; Zatelli MC; De Marinis L; Giustina A
J Clin Endocrinol Metab; 2023 Dec; 109(1):e58-e68. PubMed ID: 37606222
[TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review.
Gliga MC; Tătăranu LG; Popescu M; Chinezu L; Paşcanu MI
Rom J Morphol Embryol; 2023; 64(1):25-33. PubMed ID: 37128788
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
